Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various medical conditions worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; and diabetic retinopathy, as well as macular edema following retinal vein occlusion, including macular edema following central retinal vein occlusion and macular edema following branch retinal vein occlusion. It also provides Dupixent injection to treat atopic dermatitis in adults, and asthma; Praluent injection for heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease in adults; and Kevzara solution for subcutaneous injection for treating rheumatoid arthritis in adults. In addition, the company offers Libtayo injection to treat metastatic or locally advanced cutaneous squamous cell carcinoma; ARCALYST injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome; and ZALTRAP injection for intravenous infusion to treat metastatic colorectal cancer. Further, it offers Inmazeb injection for infection caused by Zaire ebolavirus; and develops product candidates for treating patients with eye, allergic and inflammatory, cancer, cardiovascular and metabolic, pain, infectious, and other diseases. The company has collaboration and license agreements with Sanofi; Bayer; Teva Pharmaceutical Industries Ltd.; Mitsubishi Tanabe Pharma Corporation; Alnylam Pharmaceuticals, Inc.; Roche Pharmaceuticals; and Kiniksa Pharmaceuticals, Ltd., as well as has an agreement with the U.S. Department of Health and Human Services. It has collaborations with Zai Lab Limited; Intellia Therapeutics, Inc.; Biomedical Advanced Research Development Authority; and AstraZeneca PLC. Regeneron Pharmaceuticals, Inc. was founded in 1988 and is headquartered in Tarrytown, New York.
IPO Year: 1991
Exchange: NASDAQ
Website: regeneron.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 1/7/2026 | $860.00 | Underperform → Buy | BofA Securities |
| 12/3/2025 | $767.00 | Overweight → Equal-Weight | Morgan Stanley |
| 11/24/2025 | $798.00 | Buy | Truist |
| 11/24/2025 | $255.00 | Buy | HSBC Securities |
| 11/13/2025 | $650.00 | Sector Perform | Scotiabank |
| 8/14/2025 | $890.00 | Buy | Rothschild & Co Redburn |
| 6/30/2025 | Buy → Hold | Argus | |
| 5/30/2025 | $662.00 | Outperform → Sector Perform | RBC Capital Mkts |
| 5/30/2025 | $580.00 | Overweight → Equal Weight | Wells Fargo |
| 5/14/2025 | $700.00 | Neutral → Buy | Citigroup |
Fastest customizable press release news feed in the world
TARRYTOWN, N.Y., Jan. 02, 2026 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that it will report its fourth quarter and full year 2025 financial and operating results on Friday, January 30, 2026, before the U.S. financial markets open. The Company will host a conference call and simultaneous webcast at 8:30 AM Eastern Time that day. Conference Call Information Participants may access the conference call live via webcast on the 'Investors and Media' page of Regeneron's website at https://investor.regeneron.com. To participate via telephone, please register in advance at this link. Upon registration, all telephone participants will receive a confirmation
Sanofi and Regeneron's Dupixent approved in Japan for children aged 6 to 11 years with bronchial asthma Approval based on global phase 3 program in children demonstrating Dupixent significantly reduced exacerbations (by 54% to 65%) and improved lung function compared to placebo (by 4.68% to 5.32%) Dupixent is the first and only biologic medicine to demonstrate improved lung function in this young patient group in a randomized phase 3 study, and inhibits IL-4 and IL-13, two key and central drivers of type 2 inflammation Paris and Tarrytown, NY, December 23, 2025. The Ministry of Health, Labour and Welfare in Japan has granted marketing and manufacturing authorization for Dupixent (dupil
Approval based on global Phase 3 program in children demonstrating Dupixent significantly reduced exacerbations (by 54% to 65%) and improved lung function (by 4.68% to 5.32%) compared to placebo Dupixent is the first and only biologic medicine to demonstrate improved lung function in this young patient group in a randomized Phase 3 trial, and inhibits IL-4 and IL-13, two key and central drivers of type 2 inflammation TARRYTOWN, N.Y. and PARIS, Dec. 23, 2025 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) and Sanofi today announced that the Ministry of Health, Labour and Welfare (MHLW) in Japan has granted marketing and manufacturing authorization for Dupixent® (dupilum
TARRYTOWN, N.Y., Dec. 22, 2025 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) will webcast its presentation at the 44th Annual J.P. Morgan Healthcare Conference on Monday, January 12, 2026. The presentation is scheduled for 2:15 p.m. Pacific Time (5:15 p.m. Eastern Time) and may be accessed from the "Investors & Media" page of Regeneron's website at http://investor.regeneron.com/events-and-presentations. A replay and transcript of the webcast will be archived on the Company's website for at least 30 days. About Regeneron Regeneron (NASDAQ:REGN) is a leading biotechnology company that invents, develops and commercializes life-transforming medicines for people with serio
Issued on behalf of GT Biopharma, Inc. VANCOUVER, BC, Dec. 19, 2025 /PRNewswire/ -- USA News Group News Commentary – The recent FDA approval in November of the first bispecific antibody combination for second-line blood cancer treatment marks the departure from traditional chemotherapy that oncologists have been anticipating for decades[1]. Engineered cell therapies and bispecific antibodies are now achieving response rates exceeding 90% in patients with relapsed and refractory hematologic malignancies, demonstrating the transformative power of immunotherapy in blood cancers[2]. These breakthroughs position companies like GT Biopharma, Inc. (NASDAQ:GTBP), Regeneron Pharmaceuticals, Inc. (NAS
All three dose groups (50 mg, 100 mg and 200 mg) showed impressive monotherapy efficacy, with VGPR+ (very good partial response or better) of ≥70% despite limited follow-up; evidence shows that these responses are expected to deepen over time Across all dose groups, 95% (19 of 20 patients) of all evaluable VGPR+ patients achieved minimal residual disease negative status Data featured in an ASH oral presentation; LINKER-MM4 is the first clinical trial to evaluate a BCMAxCD3 bispecific monotherapy in NDMM and is part of a broad clinical development program evaluating Lynozyfic-based regimens in earlier lines of treatment Regeneron to host virtual ‘Regeneron Roundtable' investor event to dis
TSRA-196 is a potential one-time treatment to precisely correct the genetic mutation underlying AATD, with Investigational New Drug filing expected by the end of the year Tessera to receive $150 million, inclusive of a cash upfront and equity investment from Regeneron; companies to share worldwide development costs and future profits 50:50Collaboration combines Regeneron's long-standing expertise in genetics, genetic medicines and clinical development with Tessera's pioneering Gene WritingTM and non-viral delivery platforms TARRYTOWN, N.Y. and SOMERVILLE, Mass., Dec. 01, 2025 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) and Tessera Therapeutics, Inc., today announced
Approval based on Phase 3 trials showing Dupixent significantly reduced itch and hives at 24 weeks compared to placebo In the EU, there are approximately 270,000 adults and adolescents aged 12 years and older living with CSU who remain symptomatic despite standard-of-care antihistamine treatment Dupixent, which inhibits IL-4 and IL-13, two key and central drivers of type 2 inflammation, is now approved for patients across seven chronic, inflammatory diseases in the EU TARRYTOWN, N.Y. and PARIS, Nov. 25, 2025 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) and Sanofi today announced that the European Commission (EC) has approved Dupixent® (dupilumab) for the treatment o
Sanofi and Regeneron's Dupixent approved as the first targeted medicine in the EU in over a decade for chronic spontaneous urticaria Approval based on phase 3 studies showing Dupixent significantly reduced itch and hives at 24 weeks compared to placeboIn the EU, there are approximately 270,000 adults and adolescents aged 12 years and older living with CSU who remain symptomatic despite standard-of-care antihistamine treatmentDupixent, which inhibits IL4 and IL13, two key and central drivers of type 2 inflammation, is now approved for patients across seven chronic, inflammatory diseases in the EU Paris and Tarrytown, NY, November 25, 2025. The European Commission has approved Dupixent (d
First and only FDA-approved treatment for RVO indicated for up to every 8-week dosing after an initial monthly dosing period Monthly dosing option in all approved indications provides greater dosing flexibility for more personalized patient care TARRYTOWN, N.Y., Nov. 19, 2025 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) today announced that the U.S. Food and Drug Administration (FDA) has approved EYLEA HD® (aflibercept) Injection 8 mg for the treatment of patients with macular edema following retinal vein occlusion (RVO) with up to every 8-week dosing after an initial monthly dosing period. The FDA also approved an every 4-week (monthly) dosing option for some patie
Live FDA approvals issued by the Food and Drug Administration and FDA breaking news
For Immediate Release: May 20, 2022 Today, the U.S. Food and Drug Administration approved Dupixent (dupilumab) to treat eosinophilic esophagitis (EoE) in adults and pediatric patients 12 years and older weighing at least 40 kilograms (which is about 88 pounds). Today’s action marks the first FDA approval of a treatment for EoE. “As researchers and clinicians have gained knowledge about eosinophilic esophagitis
Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.
4 - REGENERON PHARMACEUTICALS, INC. (0000872589) (Issuer)
4 - REGENERON PHARMACEUTICALS, INC. (0000872589) (Issuer)
4 - REGENERON PHARMACEUTICALS, INC. (0000872589) (Issuer)
4 - REGENERON PHARMACEUTICALS, INC. (0000872589) (Issuer)
4 - REGENERON PHARMACEUTICALS, INC. (0000872589) (Issuer)
4 - REGENERON PHARMACEUTICALS, INC. (0000872589) (Issuer)
4 - REGENERON PHARMACEUTICALS, INC. (0000872589) (Issuer)
4 - REGENERON PHARMACEUTICALS, INC. (0000872589) (Issuer)
4 - REGENERON PHARMACEUTICALS, INC. (0000872589) (Issuer)
4 - REGENERON PHARMACEUTICALS, INC. (0000872589) (Issuer)
Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.
BofA Securities upgraded Regeneron Pharma from Underperform to Buy and set a new price target of $860.00
Morgan Stanley downgraded Regeneron Pharma from Overweight to Equal-Weight and set a new price target of $767.00
Truist resumed coverage of Regeneron Pharma with a rating of Buy and set a new price target of $798.00
HSBC Securities initiated coverage of Regeneron Pharma with a rating of Buy and set a new price target of $255.00
Scotiabank initiated coverage of Regeneron Pharma with a rating of Sector Perform and set a new price target of $650.00
Rothschild & Co Redburn initiated coverage of Regeneron Pharma with a rating of Buy and set a new price target of $890.00
Argus downgraded Regeneron Pharma from Buy to Hold
RBC Capital Mkts downgraded Regeneron Pharma from Outperform to Sector Perform and set a new price target of $662.00
Wells Fargo downgraded Regeneron Pharma from Overweight to Equal Weight and set a new price target of $580.00
Citigroup upgraded Regeneron Pharma from Neutral to Buy and set a new price target of $700.00
13F-HR - REGENERON PHARMACEUTICALS, INC. (0000872589) (Filer)
10-Q - REGENERON PHARMACEUTICALS, INC. (0000872589) (Filer)
8-K - REGENERON PHARMACEUTICALS, INC. (0000872589) (Filer)
8-K - REGENERON PHARMACEUTICALS, INC. (0000872589) (Filer)
SCHEDULE 13G/A - REGENERON PHARMACEUTICALS, INC. (0000872589) (Subject)
13F-HR - REGENERON PHARMACEUTICALS, INC. (0000872589) (Filer)
10-Q - REGENERON PHARMACEUTICALS, INC. (0000872589) (Filer)
8-K - REGENERON PHARMACEUTICALS, INC. (0000872589) (Filer)
8-K - REGENERON PHARMACEUTICALS, INC. (0000872589) (Filer)
SCHEDULE 13G/A - REGENERON PHARMACEUTICALS, INC. (0000872589) (Subject)
This live feed shows all institutional transactions in real time.
SC 13G/A - REGENERON PHARMACEUTICALS, INC. (0000872589) (Subject)
SC 13G/A - REGENERON PHARMACEUTICALS, INC. (0000872589) (Subject)
SC 13G/A - REGENERON PHARMACEUTICALS, INC. (0000872589) (Subject)
SC 13G/A - REGENERON PHARMACEUTICALS, INC. (0000872589) (Subject)
SC 13G/A - REGENERON PHARMACEUTICALS, INC. (0000872589) (Subject)
SC 13G/A - REGENERON PHARMACEUTICALS, INC. (0000872589) (Subject)
SC 13G/A - REGENERON PHARMACEUTICALS, INC. (0000872589) (Subject)
SC 13G/A - REGENERON PHARMACEUTICALS, INC. (0000872589) (Subject)
SC 13G - REGENERON PHARMACEUTICALS, INC. (0000872589) (Subject)
SC 13G/A - REGENERON PHARMACEUTICALS, INC. (0000872589) (Subject)
Live Leadership Updates
TARRYTOWN, N.Y., June 24, 2025 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) today announced the launch of a pioneering matching program for donations to Good Days, an independent national non-profit charitable organization, to support Good Days' Retinal Vascular and Neovascular Disease Fund. Through this initiative, Regeneron has committed to matching donations up to a total of $200 million at a one-to-one rate for the remainder of the 2025 calendar year, enabling more patients to affordably access essential medicines that help protect their vision. "We are proud to support Good Days with this unprecedented philanthropic effort," said Leonard Schleifer, M.D., Ph.D.,
TARRYTOWN, N.Y., Jan. 30, 2024 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) today announced the formation of Regeneron Cell Medicines based on an agreement with 2seventy bio, Inc. to acquire full development and commercialization rights to its pipeline of investigational novel immune cell therapies, along with its discovery and clinical manufacturing capabilities. 2seventy bio employees who support the acquired programs will join Regeneron Cell Medicines, a newly formed research & development (R&D) unit to advance cell therapies and combination approaches in oncology and immunology. "Regeneron and 2seventy share a relentless commitment to push the boundaries of scie
NIH data show that globally less than 2% of genetic information being studied today originates from people of African ancestry1 The newly established Diaspora Human Genomics Institute (DHGI) will manage the Together for CHANGE initiative, which aims to increase available genomic data for people of African ancestry and enhance representation in STEM careers NASHVILLE, Tenn. and TARRYTOWN, N.Y. and WILMINGTON, Del. and BAGSVAERD, Denmark and BASEL, Switzerland, Oct. 18, 2023 (GLOBE NEWSWIRE) -- Meharry Medical College, along with partners Regeneron Genetics Center® (RGC™), AstraZeneca, Novo Nordisk, and Roche, today announced the launch of the Together for CHANGE™ ("Changing Healthcare for
TARRYTOWN, N.Y., April 17, 2023 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that P. Roy Vagelos, M.D., will retire from his role as Chair of the Company's Board of Directors and will not stand for reelection at the Company's 2023 Annual Meeting of Shareholders. Dr. Vagelos has served as Chair since January 1995 and will complete his current term through the conclusion of the Annual Meeting on June 9, 2023. Effective upon the conclusion of that meeting, the Board plans to appoint Leonard S. Schleifer, M.D., Ph.D., and George D. Yancopoulos, M.D., Ph.D., as Co-Chairs of the Board, in addition to their roles as President and Chief Executive Officer and P
Target knockdown and safety results support continued clinical development Regeneron and Alnylam intend to initiate a Phase 2 study in late 2022 Detailed results to be presented at an upcoming medical congress TARRYTOWN, N.Y and CAMBRIDGE, Mass., Sept. 15, 2022 /PRNewswire/ -- Regeneron Pharmaceuticals (Nasdaq: REGN) and Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY) announced today preliminary Phase 1 data supporting the clinical advancement of ALN-HSD, an investigational RNAi therapeutic targeting HSD17B13 in development for the treatment of nonalcoholic steatohepatitis (NASH). After single-dose evaluation in healthy adult volunteers (Part A), multiple doses of ALN-HSD are being studied in a
Target knockdown and safety results support continued clinical development Alnylam and Regeneron intend to initiate a Phase 2 study in late 2022 Detailed results to be presented at an upcoming medical congress Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY) and Regeneron Pharmaceuticals (Nasdaq: REGN) announced today preliminary Phase 1 data supporting the clinical advancement of ALN-HSD, an investigational RNAi therapeutic targeting HSD17B13 in development for the treatment of nonalcoholic steatohepatitis (NASH). After single-dose evaluation in healthy adult volunteers (Part A), multiple doses of ALN-HSD are being studied in adult patients with NASH (Part B). Patients in the first two Par
Live finance-specific insights
TARRYTOWN, N.Y., Jan. 02, 2026 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that it will report its fourth quarter and full year 2025 financial and operating results on Friday, January 30, 2026, before the U.S. financial markets open. The Company will host a conference call and simultaneous webcast at 8:30 AM Eastern Time that day. Conference Call Information Participants may access the conference call live via webcast on the 'Investors and Media' page of Regeneron's website at https://investor.regeneron.com. To participate via telephone, please register in advance at this link. Upon registration, all telephone participants will receive a confirmation
All three dose groups (50 mg, 100 mg and 200 mg) showed impressive monotherapy efficacy, with VGPR+ (very good partial response or better) of ≥70% despite limited follow-up; evidence shows that these responses are expected to deepen over time Across all dose groups, 95% (19 of 20 patients) of all evaluable VGPR+ patients achieved minimal residual disease negative status Data featured in an ASH oral presentation; LINKER-MM4 is the first clinical trial to evaluate a BCMAxCD3 bispecific monotherapy in NDMM and is part of a broad clinical development program evaluating Lynozyfic-based regimens in earlier lines of treatment Regeneron to host virtual ‘Regeneron Roundtable' investor event to dis
Oral presentation of Lynozyfic™ (linvoseltamab-gcpt) data in newly diagnosed multiple myeloma from LINKER-MM4, the first trial to evaluate a BCMAxCD3 bispecific antibody as a monotherapy in this setting Additional oral presentation spotlights data for odronextamab in combination with chemotherapy, without rituximab, as a frontline treatment for diffuse large B-cell lymphoma Other presentations span a broad range of hematologic conditions, including paroxysmal nocturnal hemoglobinuria and severe aplastic anemia Regeneron to host virtual ‘Regeneron Roundtable' investor event to discuss its multiple myeloma development program on Wednesday, December 10 at 8:30 a.m. ET TARRYTOWN, N.Y., Nov.
Proof-of-concept trials confirm robust anti-clotting effects for Regeneron's two mechanistically-distinct antibodies against factor XI, in patients undergoing total knee replacement Trial results consistent with prospective design of these antibodies to have distinct profiles – one to provide stronger anticoagulation and the other to have a lower risk of bleeding – potentially allowing physicians to tailor anticoagulant therapy for patients with different risk profiles Phase 3 trials in patients undergoing total knee replacement initiated as part of broad factor XI program evaluating the two antibodies across a range of patient populations and clinical settings Regeneron to host vir
TARRYTOWN, N.Y., Sept. 30, 2025 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that it will report its third quarter 2025 financial and operating results on Tuesday, October 28, 2025, before the U.S. financial markets open. The Company will host a conference call and simultaneous webcast at 8:30 AM Eastern Time that day. Conference Call Information Participants may access the conference call live via webcast on the 'Investors and Media' page of Regeneron's website at https://investor.regeneron.com. To participate via telephone, please register in advance at this link. Upon registration, all telephone participants will receive a confirmation email det
TARRYTOWN, N.Y., June 26, 2025 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that it will report its second quarter 2025 financial and operating results on Friday, August 1, 2025, before the U.S. financial markets open. The Company will host a conference call and simultaneous webcast at 8:30 AM Eastern Time that day. Conference Call Information Participants may access the conference call live via webcast on the 'Investors and Media' page of Regeneron's website at https://investor.regeneron.com. To participate via telephone, please register in advance at this link. Upon registration, all telephone participants will receive a confirmation email detailin
TARRYTOWN, N.Y., March 25, 2025 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that it will report its first quarter 2025 financial and operating results on Tuesday, April 29, 2025, before the U.S. financial markets open. The Company will host a conference call and simultaneous webcast at 8:30 AM Eastern Time that day. Conference Call Information Participants may access the conference call live via webcast on the 'Investors and Media' page of Regeneron's website at https://investor.regeneron.com. To participate via telephone, please register in advance at this link. Upon registration, all telephone participants will receive a confirmation email detai
TARRYTOWN, N.Y., Jan. 07, 2025 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that it will report its fourth quarter and full year 2024 financial and operating results on Tuesday, February 4, 2025, before the U.S. financial markets open. The Company will host a conference call and simultaneous webcast at 8:30 AM Eastern Time that day. Conference Call Information Participants may access the conference call live via webcast on the 'Investors and Media' page of Regeneron's website at https://investor.regeneron.com. To participate via telephone, please register in advance at this link. Upon registration, all telephone participants will receive a confirmati
TARRYTOWN, N.Y., Sept. 26, 2024 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that it will report its third quarter 2024 financial and operating results on Thursday, October 31, 2024, before the U.S. financial markets open. The Company will host a conference call and simultaneous webcast at 8:30 AM Eastern Time that day. Conference Call Information Participants may access the conference call live via webcast on the 'Investors and Media' page of Regeneron's website at https://investor.regeneron.com. To participate via telephone, please register in advance at this link. Upon registration, all telephone participants will receive a confirmation email deta
TARRYTOWN, N.Y., Aug. 07, 2024 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) announces the following September 2024 investor events: Investor Conference Presentations • Morgan Stanley 22nd Annual Global Healthcare Conference at 11:30 a.m. ET on Wednesday, September 4, 2024 • 2024 Wells Fargo Healthcare Conference at 12:45 p.m. ET on Thursday, September 5, 2024 The sessions may be accessed from the "Investors & Media" page of Regeneron's website at https://investor.regeneron.com/events-and-presentations. Replays and transcripts of the webcasts will be archived on the Company's website for at least 30 days. Oncology Webcast Information • European Society for Medi